| Heading: |
Alzheimer's Disease: Donanemab and Lecanemab |
| Question ID: |
1816029 |
| UIN: |
62442 |
| House: |
Commons |
| Date tabled: |
2025-06-24 |
| Asking Member ID: |
5262 |
| Asking Member display name: |
Alex Easton
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Alex Easton
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on its decision not to recommend the use of donanemab and lecanemab for Alzheimer's patients by the NHS. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-01 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including the progress of specific appraisals. NICE develops its guidance independently in line with its established ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |